GGrantIndex
← Leaderboards

Molly A Hughes

University Of Virginia Charlottesville

$6,444,579
Attributed
$6,444,579
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $631K · FY200824
$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$6,444,579 · 8

By mechanism

R01$4,619,915 · 2
R21$1,427,935 · 3
K08$366,729 · 1
R13$30,000 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of Virginia Charlottesville

Same institution · by research overlap

Others in their field

Top investigators on “Pathogen

Research focus

PathogenAntibioticsInfectionBaseFoundationsMediatingBacteriaResistanceIn VivoPhenotypeExhibitsInsightReceptorInnovationInvadedMulti-Drug ResistanceIn VitroCellsLeadLifeBiologicalImmuneHost DefenseMicroorganism

Grant awards (20)

A unique strategy for reshaping the antibiotics model: chemokine-inspired therapeutics for targeting the host and pathogen to counter infections caused by multidrug-resistant bacteria$614,218
R01 · FY2024 · AI · contact PI
A unique strategy for reshaping the antibiotics model: chemokine-inspired therapeutics for targeting the host and pathogen to counter infections caused by multidrug-resistant bacteria$613,109
R01 · FY2023 · AI · contact PI
A unique strategy for reshaping the antibiotics model: chemokine-inspired therapeutics for targeting the host and pathogen to counter infections caused by multidrug-resistant bacteria$606,542
R01 · FY2022 · AI · contact PI
A unique strategy for reshaping the antibiotics model: chemokine-inspired therapeutics for targeting the host and pathogen to counter infections caused by multidrug-resistant bacteria$630,959
R01 · FY2021 · AI · contact PI
A unique strategy for reshaping the antibiotics model: chemokine-inspired therapeutics for targeting the host and pathogen to counter infections caused by multidrug-resistant bacteria$598,787
R01 · FY2020 · AI · contact PI
Elucidating a unique bacterial strategy that protects susceptible bacteria from antibiotic killing and promotes the genetic transmission of antimicrobial resistance$245,777
R21 · FY2019 · AI · contact PI
Elucidating a unique bacterial strategy that protects susceptible bacteria from antibiotic killing and promotes the genetic transmission of antimicrobial resistance$205,298
R21 · FY2018 · AI · contact PI
Bacillus anthracis Targets Involved in Chemokine-Mediated Antimicrobial Activity$395,000
R01 · FY2016 · AI · contact PI
Bacillus anthracis Targets Involved in Chemokine-Mediated Antimicrobial Activity$395,000
R01 · FY2015 · AI · contact PI
Bacillus anthracis Targets Involved in Chemokine-Mediated Antimicrobial Activity$395,000
R01 · FY2014 · AI · contact PI
Bacillus anthracis Targets Involved in Chemokine-Mediated Antimicrobial Activity$371,300
R01 · FY2013 · AI · contact PI
2011 Chemical & Biological Terrorism Defense Gordon Research Conference (GRC) and$15,000
R13 · FY2011 · AI · contact PI
Innate Immune Recognition of B. anthracis$189,375
R21 · FY2009 · AI · contact PI
2009 Chemical and Biological Terrorism Defense Gordon Research Conference$15,000
R13 · FY2009 · AI · contact PI
Innate Immune Recognition of B. anthracis$227,250
R21 · FY2008 · AI · contact PI
Studies on Macrophage Resistance to Anthrax Lethal Toxin$266,219
R21 · FY2004 · AI
Identification of E. histolytica virulence factors$122,243
K08 · FY2004 · AI
Studies on Macrophage Resistance to Anthrax Lethal Toxin$294,016
R21 · FY2003 · AI
Identification of E. histolytica virulence factors$122,243
K08 · FY2003 · AI
Identification of E. histolytica virulence factors$122,243
K08 · FY2002 · AI